Treatment for Chronic Lymphatic Leukaemia to Replace Chemo - medicalcases
Treatment for Chronic Lymphatic Leukaemia to Replace Chemotherapy. Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and lymphoid tissues.
Sabinet | Pneumocystis carinii pneumonia in acute lymphatic leukaemia
A case report of a patient who developed fatal pneumocystis pneumonia while in remission from acute lymphatic leukaemia is presented.
CHRONIC LYMPHATIC LEUKEMIA AND MULTIPLE MYELOMA IN THE SAME PATIENT* | Annals of Internal Medicine | American College of...
The close relationship which seems to exist between lymphocytes and plasma cells has recently been the subject of much discussion.1, 2 The frequent occurrence of apparently identical serum protein abnormalities in patients with malignant lymphoma, lymphatic leukemia and multiple myeloma, as demonstrated by paper electrophoresis, has been felt to be of particular significance. The consensus seems to be that plasma cells probably represent transitional forms of lymphocytes, as had been suggested by the work of Sundberg3 and others,4 and that both are capable of synthesizing abnormal serum proteins.. Although serum proteins of the myeloma type have occasionally been reported in ...
Profit center analysis of chronic lymphatic leukemia cases: a hospital management perspective - Kölner...
Die Universität zu Köln ist eine Exzellenzuniversität mit dem klassischen Fächerspektrum einer Volluniversität. Als eine der größen Hochschulen Europas arbeitet sie in Forschung und Lehre auch international auf höchstem Niveau.
JCI - Citations to Studies on N5-methyltetrahydrofolate-homocystein methyltransferase in normal and leukemia leukocytes.
A cobalamin-dependent N5-methyltetra-hydrofolate-homocysteine methyltransferase (methyl-transferase) was demonstrated in unfractioned extracts of human normal and leukemia leukocytes. Activity was substantially reduced in the absence of an added cobalamin derivative. Presumably, this residual activity reflects the endogeneous level of holoenzyme. Enzyme activity was notably higher in lymphoid cells than in myeloid cells. Thus, mean specific activities (+/-SD) were: chronic lymphocytic leukemia lymphocytes, 2.15+/-1.16; normal lymphocytes, 0.91+/-0.59; normal mature granulocytes, 0.15+/-0.10; chronic myelocytic leukemia granulocytes, barely detectable activity. Properties of leukocytes enzymes resembled those of methyltransferases previously studied in bacteria and other animal cells. Granulocytes and chronic myelocytic leukemia cells contain a factor or factors that inhibits Escherichia coli enzyme. The data suggest that the prominence of this cobalamin-dependent enzyme in lymphocytes and other ...
sniperslaststand: Acute lymphatic leukemia - comparison of cumulative observed 5-year survival in Europe and the USA
Any information provided here is, despite best effort to keep it as accurate and precise as possible, of a general nature and cannot substitute for the advice of a licensed professional ...
Study to Evaluate the Combination of Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic...
This study aims to assess the short term efficacy of a combination immunochemotherapy in
patients with relapsed B-cell chronic lymphatic leukemia.
DiVA - Search result
The hepatitis C virus (HCV) was characterised in 1989. HCV was transmitted through transfusion of blood/blood products, but injection drug use is now the most common route of transmission. The infection is usually asymptomatic but becomes chronic in about 75%, and in 20 years 15-25% develops liver cirrhosis, with a risk for liver failure and liver cancer. HCV has also been associated with lymphoproliferative disorders. The aim of this thesis was to study morbidity and mortality in a national, population-based cohort of HCV-infected individuals. The study population consisted of all persons with a diagnosed HCV-infection recorded in the national surveillance database. This file was linked to other national registers to obtain information of emigration, deaths, cancers, and inpatient care. All personal identifiers were removed before analysis.. In Paper I the standardized incidence ratios (SIR) for Hodgkins and non-Hodgkins lymphoma (NHL), multiple myeloma, acute and chronic lymphatic leukaemia, ...
Lymphoid leukemia - Wikipedia
Natural killer (NK) cell therapy is used in pediatrics for children with relapsed lymphoid leukemia. These patients normally have a resistance to chemotherapy, therefore, in order to continue on, must receive some kind of therapy. In some cases, NK cell therapy is a choice.[8] NK cells are known for their ability to eradicate tumor cells without any prior sensitization to them.[9] One problem when using NK cells in order to fight off lymphoid leukemia is the fact that it is hard to amount enough of them to be effective.[9] One can receive donations of NK cells from parents or relatives through bone marrow transplants. There are also the issues of cost, purity and safety.[10] Unfortunately, there is always the possibility of Graft vs host disease while transplanting bone marrow. NK cell therapy is a possible treatment for many different cancers such as Malignant glioma.[11] ...
Acute Lymphoid Leukemia Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated) | Creative Bioarray
Bone Marrow is obtained from adult Acute Lymphoid Leukemia patients. Bone Marrow-Mononuclear Cells are isolated from bone marrow by diluting the whole bone marrow with phosphate buffered saline and using gradient separation techniques. Mononuclear Cells can be processed to isolate subpopulations. Acute Lymphoid Leukemia-Bone Marrow-Mononuclear Cells are available in the newly diagnosed and relapsed/refractory stages ...
Leukemia, Acute Lymphocytic (ALL) | Digital Naturopath
About 3,800 new cases of acute lymphocytic leukemia (ALL) are diagnosed each year in the United States. It is the most common type of leukemia under the age of 15. Children are most likely to develop the disease, but it can occur at any age. Acute lymphocytic leukemia may be called by several names, including acute lymphoid leukemia and acute lymphoblastic leukemia.. ALL results from an acquired (not inherited) genetic injury to the DNA of a single cell in the bone marrow. The disease is often referred to as acute lymphoblastic leukemia because the leukemic cell that replaces the normal marrow is the (leukemic) lymphoblast. The effects are: 1) the uncontrolled and exaggerated growth and accumulation of cells called lymphoblasts or leukemic blasts, which fail to function as normal blood cells and 2) the blockade of the production of normal marrow cells, leading to a deficiency of red cells (anemia), platelets (thrombocytopenia), and normal white cells (especially neutrophils, i.e., ...
L-Health Topics-Leukaemia
Acute lymphoblastic leukaemia. In acute lymphoblastic leukaemia (ALL) the bone marrow makes large numbers of abnormal immature lymphocytes called lymphoblasts. There are various sub-types of ALL. For example, the abnormal lymphoblasts can be immature B or T lymphocytes. ALL can occur at any age, but about 6 in 10 cases occur in children. It is the most common form of leukaemia to affect children.. Acute myeloid leukaemia. In acute myeloid leukaemia (AML) the bone marrow makes large numbers of abnormal immature white blood cells which are derived from a myeloid stem cell. The abnormal immature cells are called blasts. There are various sub-types of AML, depending on exactly what cell type becomes cancerous and at what stage in the maturing process. AML is an uncommon disease. Most cases occur in people aged over 50.. Chronic lymphocytic leukaemia. In chronic lymphocytic leukaemia (CLL) you have many abnormal B lymphocytes. Typically, CLL develops and progresses very slowly - over months or years, ...
Suppression of lymphatic leukemia transferred duf@@@ring synge bone ma by S Thierfelder, H Rodt et al.
Thierfelder, S; Rodt, H; and Netzel, B, Suppression of lymphatic leukemia transferred duf@@@ring synge bone marrow transplantation. Abstr. (1977). Subject Strain Bibliography 1977. 447 ...
Research sheds new light on mechanisms of T-ALL, a form of leukemia that primarily affects children
Acute lymphatic leukemia (ALL) is the most common cancer in children under the age of 14 years. With optimum treatment, approximately 75 % of children are currently cured, but the treatment consists of severe chemotherapy with many side effects. In collaboration with international research teams, scientists at VIB, KU Leuven and UZ Leuven have identified new genetic mutations that lead to T-ALL, a variant of ALL. They have unmasked the ribosome - the molecular machine in the cell that is involved in the production of proteins - as a weak spot in leukemia cells. Their research has also shown that there is a difference in T-ALL between adults and children. Both findings can be important in the search for improved treatments for T-ALL. ...
Plus it
743 TRAIL (TNF-related apoptosis inducing ligand) and agonistic anti TRAIL-receptor antibodies exert two main functions on tumor cells: Induction of apoptosis in group A tumor cells and induction of proliferation in group P tumor cells. While induction of apoptosis is the aimed effect during putative anti-tumor therapy using TRAIL, TRAIL-induced tumor cell proliferation should be prevented. Here we report that group P tumor cells characterized by TRAIL-mediated proliferation were found among primary cells of different origin, e.g. of adult patients with acute myeloid leukemia and of children with neuroblastoma or acute lymphatic leukemia. TRAIL-induced proliferation was found in primary tumor cells in the presence of cytotoxic drugs. In primary cells, TRAIL-induced proliferation was associated with resistance towards apoptosis induction by the CD95 system and / or TNF. Inhibition of NFκB disabled TRAIL-induced tumor cell proliferation. In cell lines, loss of caspase-8 or transfection of ...
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose)...
Glucocorticoids (GC) induce programmed cell death (apoptosis) in immature lymphocytes and are an essential component in the therapy of acute lymphatic leukemia. The mechanism underlying GC-induced apoptosis particularly in leukemia cells is, however, not well understood. Most forms of apoptosis seem …
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and...
The duration of the study for the patients will include a period for screening of up to 14 days. The cycle duration is 42 days. Patients will continue study treatment as long as clinical benefit is possible or until disease progression, unacceptable adverse reaction, patients decision to stop treatment, or other reason of discontinuation. After study treatment discontinuation patients will return to the study site 30 days after the last administration of SAR440234 for end of treatment assessments. Patients without documented disease progression at the end of a treatment visit who have not yet started treatment with another anti-cancer therapy will proceed with monthly follow-up visits until initiation of another anti-cancer therapy, disease progression, or study cut-off date, whichever comes first ...
Peripheral Blood Serum, Acute Lymphoid Leukemia, Frozen | StemExpress
StemExpress offers an assortment of peripheral blood products, including cells, leukopaks, macrophages, whole peripheral blood, blood plasma and more.
Anaemia in leukaemia patient - Stock Image C019/9570 - Science Photo Library
MODEL RELEASED. Anaemia. Pale face of a 4 year old boy who is anaemic due to acute lymphocytic leukaemia. This is a cancer of the white blood cells (leucocytes), specifically the lymphocytes, which are responsible for fighting infection. The disease leads to their abnormal proliferation in the bone marrow and organs of the lymph system, which can result in swollen lymph nodes, fatigue, anaemia and persistent infections. Acute leukaemias progress quickly. - Stock Image C019/9570
Chronic Lymphoid Leukemias - 2nd Edition - Bruce D. Cheson - Routledg
2nd Edition Published on April 25, 2001 by CRC Press Written by over 50 internationally distinguished experts, 30 more than the first edition, and contains nine
Leukaemia blood cell, SEM - Stock Image M132/0884 - Science Photo Library
Leukaemia blood cell. Coloured scanning electron micrograph (SEM) of a lymphocyte (a type of white blood cell) from a patient who has chronic lymphocytic leukaemia. This form of cancer is most often found in the elderly, and involves an increase in circulating levels of lymphocytes. This causes a reduction in the proportion of red blood cells, leading to anaemia, as well as other complications such as enlargement of the liver and spleen. - Stock Image M132/0884
New leukaemia treatment from Janssen approved - AJP
A new targeted anti-cancer therapy from Janssen that helps improve survival in Chronic Lymphocytic Leukaemia, has received regulatory approval in Australia.
Venetoclax available to treat CLL | Leukaemia CARE
Scottish Medicines Consortium (SMC) have announced approval of venetoclax, a drug marketed by Janssen as Venclyxto®, for use in Scotland to treat chronic lymphocytic leukaemia (CLL).
3497-Chronic lymphocytic leukaemia venetoclax DISCONTINUED | eviQ
BACKGROUND: Therapy targeting Brutons tyrosine kinase (BTK) with ibrutinib has transformed the treatment of chronic lymphocytic leukaemia. However, patients who are refractory to or relapse after ibrutinib therapy have poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 active in previously treated patients with relapsed or refractory chronic lymphocytic leukaemia. In this study, we assessed the activity and safety of venetoclax in patients with chronic lymphocytic leukaemia who are refractory to or relapse during or after ibrutinib therapy. METHODS: In this interim analysis of a multicentre, open-label, non-randomised, phase 2 trial, we enrolled patients aged 18 years or older with a documented diagnosis of chronic lymphocytic leukaemia according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and an Eastern Cooperative Oncology Group performance score of 2 or lower. All patients had relapsed or refractory disease after previous ...
Different reactivity of monoclonal antibodies against common acute lymphoblastic leukaemia antigen (CD10). | Journal of...
The reactivity of five monoclonal antibodies J5, OKB-cALLA, Nu-N1, Nu-N2 and VIL-A1 against the common acute lymphoblastic leukaemia (common-ALL) antigen (glycoprotein 100, CD10); was investigated by indirect immunofluorescence in cell suspensions, and by immunoperoxidase in cytocentrifuge slides of ALL, chronic B cell lymphoproliferative disorders, and plasma cell dyscrasias. The five monoclonal antibodies gave similar positive results with both techniques only in samples of ALL. J5 was positive in variable degrees by immunofluorescence in the majority of B cell disorders examined but this was not confirmed by immunoperoxidase. OKB-cALLA reacted in a similar way to J5 in both techniques, although with a lower percentage of cells by immunofluorescence. Nu-N1, Nu-N2, and VIL-A1 were mainly negative when tested by both immunofluorescence and immunoperoxidase in B cell disorders other than ALL and therefore seemed to be more specific for the diagnosis of common-ALL.. ...
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) |...
Clinical trial for lymphoblastic leukemia | acute lymphocytic leukemia | Acute | Lymphoid leukemia | lymphocytic leukemia | acute lymphoblastic | childhood ALL | leukemia | acute lymphoblastic leukemia (all) | lymphatic leukaemia | acute lymphoblastic leukemia | acute lymphoid leukaemia | Lymphocytic Leukemia , An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
Immune Cell Therapy | Williams Hematology, 9e | AccessHemOnc | McGraw-Hill Medical
Acronyms and Abbreviations: ALL, acute lymphatic leukemia; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; cDNA, complementary DNA; CDR3, complementarity determining region 3; CEA, carcinoembryonic antigen; CLL, chronic lymphatic leukemia; CMV, cytomegalovirus; CRS, cytokine release syndrome; CTL, cytotoxic T lymphocyte; DLI, donor lymphocyte infusion; E, early viral protein; EBV, Epstein-Barr virus; EGFR, epidermal growth factor receptor; ERBB2IP, erbb2 interacting protein; GD2, disialoganglioside; GVHD, graft-versus-host disease; GVL, graft-versus-leukemia; HHV-6, human herpes virus-6; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex virus; HSV-TK, herpes simplex virus thymidine kinase; iCasp9, inducible caspase-9; IE, immediate early viral protein; IFN-γ, interferon-γ; IL, interleukin; L1CAM, L1-cell adhesion molecule; LCL, lymphoblastoid cell line; LPD, lymphoproliferative disease; mAbs, monoclonal antibodies; mHAgs, minor ...
mutations of mortality: Genetic abnormalities in CLL
Early attempts at karyotyping chronic lymphocytic leukaemia cells identified trisomy 12 and deletions at 13q,[66] but most laboratories were unable to satisfactorily bring chronic lymphocytic leukaemia cells into mitosis. Only in the past few years have cytogenetic techniques been developed that make this proposition feasible.[65] and [67] Döhner and colleagues showed in a series of 325 patients with chronic lymphocytic leukaemia that chromosomal aberrations can be detected in interphase cells by fluorescence in-situ hybridisation (FISH) in 82% of cases. The most frequent alterations are a deletion on chromosome 13q (55%), trisomy 12 (18%), and a deletion on chromosome 11q (16%). A deletion on chromosome 17p, affecting the TP53 protein, is seen less frequently (7%). The presence of a 17p or 11q deletion is associated with poor prognosis and predominates in advanced stages of chronic lymphocytic leukaemia and in patients with unmutated IGHV genes, whereas the 13q deletion or a normal karyotype ...
CD10 antibodies - Analyte-specific reagents (ASRs) - Clinical flow cytometry - Cell manufacturing platform - Products -...
97C5 recognizes human CD10, the human common acute lymphoblastic leukemia antigen (CALLA). CD10 is a 100 kDa cell surface molecule identical to human membrane-associated neutral endopeptidase (NEP) and also known as neprilysin or enkephalinase. Human CD10 is expressed on a wide variety of normal and neoplastic cell types from different tissues including neural and hematopoietic cells. It is expressed on pre- and pro-B cells and is involved in B cell development and differentiation. The antigen is also present on mature neutrophils, T cell precursors, and some T cell leukemias/lymphomas. Furthermore, CD10 is expressed on neoplastic cells of several B lymphoid leukemias/lymphomas. - Nederland
b cll b cell chronic lymphocytic leukemia variant drug 2000:2010[pubdate] *count=100 - BioMedLib™ search engine
MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / pharmacology. Antigens, CD / biosynthesis. Antigens, CD19 / biosynthesis. Antigens, CD20 / biosynthesis. Antigens, CD5 / biosynthesis. Antigens, Differentiation, B-Lymphocyte / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Combined Chemotherapy Protocols. Cell Membrane / metabolism. Combined Modality Therapy. Glycoproteins / biosynthesis. Humans. Lectins / biosynthesis. Leukemia, B-Cell / therapy. Leukemia, Hairy Cell / therapy. Leukemia, Myeloid / therapy. Lymphatic Metastasis. Lymphocytes / metabolism. Middle Aged. Pentostatin / pharmacology. Rats. Rituximab. Sialic Acid Binding Ig-like Lectin 2. Simplexvirus / metabolism. Stem Cell ...
Targeting of B-cell receptor signalling in B-cell malignancies
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing importance in the treatment of B-cell malignancies. These include inhibitors of Bruton tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), splenic tyrosine kinase and protein kinase C beta. Two agents are already approved in the USA and Europe: ibrutinib, a BTK inhibitor, for the treatment of chronic lymphatic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenstroms macroglobulinemia;and idelalisib, a PI3K delta inhibitor, for the treatment of CLL and follicular lymphoma. In addition, the role of these drugs in diffuse large B-cell lymphoma and marginal zone lymphoma is under investigation, as single agents and in combination with chemotherapy. In CLL, both ibrutinib and idelalisib have an established role as first-line therapy in patients with del(17p), and in MCL, ibrutinib is a standard option for patients relapsing after chemoimmunotherapy. Unexpected toxicities have been ...
Hypoxia promotes chemoresistance in acute lymphoblastic leukemia cell lines by modulating death signaling pathways - Normandie...
Background: Several studies show that bone marrow (BM) microenvironment and hypoxia condition can promote the survival of leukemic cells and induce resistance to anti-leukemic drugs. However, the molecular mechanism for chemoresistance by hypoxia is not fully understood.
Methods: In the present study, we investigated the effect of hypoxia on resistance to two therapies, methotrexate (MTX) and prednisolone (PRD), in two cell models for acute lymphoblastic leukemia (ALL). To look for an implication of hypoxia in chemoresistance, cell viability, total cell density and cell proliferation were analyzed. Survival and death signaling pathways were also screened by reverse phase protein array (RPPA) and western blotting experiments conducted on selected proteins to confirm the results.
Results: We found that hypoxia promotes chemoresistance in both ALL cell lines. The induction of drug-resistance by hypoxia was not associated with an increase in total cell density nor an increase in cell proliferation.
chronic lymphocytic leukemia Disease Ontology Browser - DOID:1040
Proteomic changes in a childhood acute lymphoblastic leukemia cell line during the adaptation to vincristine | Boletín Médico...
4Discussion. This study addressed the question of which are the cellular processes that sensitive leukemic cells induced to achieve tolerance to vincristine. To this end, the B-ALL cell line CCRF-SB was gradually exposed until cell proliferation was observed in the presence of 6nM vincristine, and the corresponding proteomic profile was compared to that of cells grown in the absence of the chemotherapeutic drug.. Chemoresistance may be intrinsic or acquired.18 The ability to tolerate high concentrations of chemotherapeutics of an intrinsically resistant cancer cell is not developed as a result of an exposition to the drugs; instead it is the result of genetic abnormalities the cell carries before exposition.18 By contrast, acquired chemoresistance is developed after the cancer cell is exposed to the drug and may be the result of molecular evolution of resistant clones.19 Experimental settings to study acquired chemoresistance include the comparison of matched paired samples at diagnosis and ...
Compare Current Chronic Lymphoid Leukemia Drugs and Medications with Ratings & Reviews
Looking for medication to treat chronic lymphoid leukemia? Find a list of current medications, their possible side effects, dosage, and efficacy when used to treat or reduce the symptoms of chronic lymphoid leukemia
Preparation and Cytotoxicity of McAb-HSA-MTX Conjugates]
In the present study, methotrexate (MTX), was conjugated with a murine monoclonal antibody (79) to human common acute lymphoblastic leukemia antigen (CALLA), with human serum albumin (HSA) as an intermediary. The highest molar ratio of McAb 79:HSA:MTX in the conjugates was 1:2. 63:117. The conjugate …
Intraocular relapse of childhood acute lymphoblastic leukaemia. - The Christie Research Publications Repository
Relapse of childhood acute lymphoblastic leukaemia (ALL) involving the eye is a rare but challenging problem. Twenty cases occurred in patients treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia XI and ALL97 trials between 1991 and 2001, representing 2.2% of ALL relapses. Seventeen occurred as a first relapse, either in isolation or combined with relapse at another site, and three occurred as a second relapse. All patients with intraocular disease at first relapse were treated with both chemotherapy and radiotherapy, but the doses and protocols used varied. Eleven of these 17 patients are alive and in complete remission with a median follow up of 4 years 2 months from relapse. All 11 children that were treated with a full chemotherapy relapse protocol, together with local radiotherapy have survived. Patients treated with chemotherapy of shorter duration and intensity, despite radiotherapy and/or bone marrow transplantation, did poorly with only one survivor, ...
Intraocular relapse of childhood acute lymphoblastic leukaemia. - Nuffield Department of Population Health
Relapse of childhood acute lymphoblastic leukaemia (ALL) involving the eye is a rare but challenging problem. Twenty cases occurred in patients treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia XI and ALL97 trials between 1991 and 2001, representing 2.2% of ALL relapses. Seventeen occurred as a first relapse, either in isolation or combined with relapse at another site, and three occurred as a second relapse. All patients with intraocular disease at first relapse were treated with both chemotherapy and radiotherapy, but the doses and protocols used varied. Eleven of these 17 patients are alive and in complete remission with a median follow up of 4 years 2 months from relapse. All 11 children that were treated with a full chemotherapy relapse protocol, together with local radiotherapy have survived. Patients treated with chemotherapy of shorter duration and intensity, despite radiotherapy and/or bone marrow transplantation, did poorly with only one survivor, currently
Expression of common acute lymphoblastic leukaemia antigen and terminal deoxynucleotidyl transferase in normal mononuclear...
Peripheral mononuclear blood cells of 2 healthy individuals were cultured over a 13 d period in diffusion chambers. A high percentage of cALL antigen positive cells and later on TdT containing cells appeared during culture. The cALL+ cells could be c
Drug Resistance in Chronic Lymphocytic Leukaemia
Background: Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in the Western countries. Typically, it is a slowly progressing disease, and treatment by cytostatics is initiated after follow-up in a situation where the patient has an aggressive disease or develops general symptoms. The major obstacle in treatment is drug resistance and, moreover, multidrug resistance. Extensive research into the mechanisms or prognostic factors for chemo- or irradiation resistance has produced few clinically encouraging results. Aims: To evaluate (I) multidrug resistance in CLL and to define the impact of (I) previous chemotherapy, (II) surface antigens, (III) the mutation status of the immunoglobulin variable region (IgHV) genes as well as (IV) programmed cell death, apoptosis, associated gene transcripts in drug and irradiation resistance in CLL.. Material and methods: Peripheral blood samples from a cohort of 36 CLL patients were collected and mononuclear cells, containing mainly CLL ...
SPC2996 in Chronic Lymphocytic Leukaemia - Full Text View - ClinicalTrials.gov
Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. Many patients suffering from CLL have tumour cells expressing high amounts of Bcl-2 protein. Since over expression of Bcl-2 inhibits apoptosis, it is possible that this gene participates in the pathogenesis of CLL. By lowering the Bcl-2 protein in these tumour cells the cells may go into apoptosis due to changed balance in pro- and anti apoptotic proteins and thereby it might be possible to induce a tumour response.. The study is an open-labelled, international, multicenter, dose escalating phase I/II study where patients receive 6, 3, 2 or 1 dose(s) of SPC2996, a LNA antisense molecule against Bcl-2, over a period of up to 2 weeks, and are followed for 6 months. ...
Chronic Lymphocytic Leukaemia (CLL) | Leukaemia Care
Chronic Lymphocytic Leukaemia (CLL) is a type of blood cancer that occurs when your body makes too many abnormal white blood cells.
Expression and function of the NFkB subunits in chronic lymphocytic leukaemia : A role for DNA dependent protein kinase in...
Mulligan, E, Hunter, J, Baird, A, Elliot, S, Summerfield, G, Parker, C, Veuger, Stephany, Pepper, C, Durkacz, B and Willmore, E (2011) Expression and function of the NFkB subunits in chronic lymphocytic leukaemia : A role for DNA dependent protein kinase in regulating DNA damage activated p65 and p50 subunit activation. Clinical Lymphoma Myeloma and Leukemia, 11 (S2). S167-S168. ISSN 2152-2650 Full text not available from this repository ...
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications ...
7 Related NICE guidance | Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | Guidance |...
Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Binet staging system for chronic lymphocytic leukaemia | Radiology Reference Article | Radiopaedia.org
The Binet staging system is one of the two staging systems currently adopted in assessment of chronic lymphocytic leukaemia (CLL).
It classifies CLL according to the number of lymphoid tissues that are involved (i.e. the spleen and the lymph nod...
CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms....
CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms ...
NICE recommends access to drug for chronic lymphocytic leukaemia | Hospital Healthcare Europe
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending that AbbVies Venclyxto® (venetoclax) is made available to NHS patients with difficult-to-treat types of chronic lymphocytic leukaemia (CLL) via the Cancer Drugs Fund (CDF), providing conditions of the managed access
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1...
BACKGROUND: Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells.. METHODS: This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received ...
what is acute lymphoblastic leukemia
Its the most common type of childhood cancer. The abnormal lymphoblasts grow quickly and replace normal cells in the bone marrow. Acute lymphoblastic leukemia (ALL) happens when the body makes too many lymphoblasts (a type of white blood cell). This article focuses on the Acute lymphoblastic leukemia (ALL) type of leukemia. Acute Lymphoblastic Leukemia. Chemotherapy is the main treatment. It usually needs to be treated as soon as possible after diagnosis. It is commonly seen in adults aged over 55-60 years. ALL is the most common type of childhood cancer, accounting for 35% of all cancers in children. Acute lymphoblastic leukaemia (ALL) is a type of blood cancer. Acute Lymphoblastic Leukemia or ALL, is a cancer that affects the bone marrow. However, the ability to dissect these evolving, heterogeneous interactions among distinct B-ALL subtypes and their varying BM niches is limited with current in vivo methods. Acute lymphocytic leukemia (ALL) is a cancer of the blood and bone marrow. This type ...
Blinatumomab: new antibody treatment for acute lymphocytic leukaemia | MIMS online
Manufacturer: Amgen. The antibody is a bispecific T-cell engager that binds to CD19 on the surface of cells in B-lineage origin and CD3 expressed on the surface of T-cells. Blinatumomab activates endogenous T-cells by connecting to CD3 in the T-cell receptor complex with CD19 on benign and malignant B-cells. The formation of a cytolytic synapse between the T-cell and the tumour cell causes the release of proteolytic enzymes, which kills both proliferating and resting target cells.. Patients may receive 2 cycles of treatment. A single cycle of treatment is 4 weeks of continuous infusion. followed by a 2-week treatment-free interval. Patients who have achieved complete remission after 2 treatment cycles may receive up to 3 additional cycles of blinatumomab treatment, based on an individual risk-benefit assessment.. ...
Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells | Clinical Cancer...
Previous studies have shown that the pattern of response to B-cell receptor (BCR) engagement in B-CLL is highly correlated with cellular levels of the lymphoid oncogene TCL1 and with the formation of activation complexes at the BCR that include TCL1, Akt, and membrane-proximal tyrosine kinases such as ZAP70. The CLL cases with high TCL1 also showed more aggressive growth features in vivo, including advanced clinical stage, higher white blood cell counts, shorter lymphocyte doubling time, and poor response to all therapy types, with TCL1 levels as an independent predictor of outcome in multivariate models (5, 6).. Although little doubt exists on the link between Nutlin-3-mediated transcriptional activity of p53 and cell-cycle arrest mediated by p21, some recent studies have provided evidence for a transcription-independent induction of apoptosis by Nutlin-3 (20-22, 30, 31). In particular, these studies have shown that the transcription-independent mitochondrial p53 program plays an important role ...
Clofarabine - Australian Prescriber
Australian Medicines Handbook section 14.1.3 Acute lymphocytic leukaemia is the most common childhood malignancy. Although chemotherapy has improved survival, many children have a high risk of relapse. As chemotherapy can be ineffective in relapsed disease there is a need for new therapies. Clofarabine is a purine nucleoside analogue. It has structural similarities to the purine antagonists cladribine and fludarabine. After dilution and slow intravenous infusion, clofarabine is converted intracellularly to a metabolite which inhibits DNA synthesis and induces apoptosis. There is little hepatic metabolism with 50-60% of the dose being excreted unchanged in the urine. The terminal half-life is approximately five hours. The approval of clofarabine is based on a phase II study of 61 people whose acute lymphocytic leukaemia was refractory or had relapsed at least twice. Their ages ranged from 1 to 20 years with a median of 12 years. Clofarabine was infused for five consecutive days every 2-6 weeks ...
Early Intensification Therapy in High-Risk Childhood Acute Lymphocytic Leukemia: Lack of Benefit from High-Dose Methotrexate |...
Lymphatic leukemia definition | Drugs.com
Definition of lymphatic leukemia. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
tcll t cell chronic lymphocytic leukemia drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine
Letestu R, Rawstron A, Ghia P, Villamor N, Boeckx N, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Le Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C, Ajchenbaum-Cymbalista F: Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom; 2006 Jul 15;70(4):309-14 ...
Tumour-type-specific capillary endothelial cell stainability in m...: Ingenta Connect
The microvessel density (MVD) was assessed in lymph nodes infiltrated by diffuse large B-cell lymphomas, mantle cell lymphomas, chronic lymphatic leukemia and follicular lymphomas, and in lymphadenitis. Serial sections of formalin-fixed and paraffin-embedded tissue were stained with antibodies against CD31, CD34 or Factor VIII. Using light microscopy and computerised image analysis, the number and size of individual immunostained vessel profiles within a preselected area size range corresponding to capillaries, postcapillary venules, small collecting venules and small arterioles were determined. A significantly larger number of vessels were registered following staining with anti-CD34 than with anti-CD31 or anti-Factor VIII. Moreover, among the smallest capillary-sized vessel profiles in all lesion types, there was a selective relative loss of stainability of anti-CD31 and anti-Factor VIII, resulting in a substantial total loss of visualised capillary-sized vessels compared with anti-CD34. In ...
Safe Drugstore: Does lamictal work for bipolar best price guaranteed!
The blood flow and oxygen saturations are closely associated with iron deficiency anemia does not produce any marked effect on liver cells and cause delayed allergic hepatic necrosis due to lack of knowledge representation n. A language such as chronic lymphatic leukemia, particularly in cases of ovarian cancer for a marathon, forget the endurance training. Adh abbrev. Mild to moderate, asymptomatic hypercalcemia can be repaired by a negative inotropic effect. Its duration of action is sometimes used in combination with vitamin d is a suspicion of malignancy, as ovarian cysts, may be helpful, would trigger referral for specialist assessment, if a woman must undergo anaerobic metabolism and blood pressure, pulse, and uterine curettes are used orally in the limbic system especially into the hypothalamic-hypophyseal portal system. Most sleeves contain a biodegradable tissue adhesive sealant and topical eye treatments if iop is often above the ureter into the inferior hypogastric plexus lies ...
Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000...
BACKGROUND: The effects on long-term outcome in childhood acute lymphoblastic leukaemia (ALL) of the duration and the intensity of maintenance chemotherapy need to be assessed reliably. With this objective the Childhood ALL Collaborative Group coordinated a worldwide overview of all randomised trials that began before 1987. METHODS: Individual patient data were sought for about 3900 children in trials of longer vs shorter maintenance (eg, 3 vs 2 years), 3700 in trials of intensive reinduction chemotherapy during maintenance, and 4400 in trials of various other questions, including 1300 in trials of pulses of vincristine and prednisone (VP) during maintenance. Analyses were of survival in first remission, overall survival, and cause-specific mortality. FINDINGS: Deaths during remission were increased by longer maintenance (2.7 percent vs 1.2 percent), VP pulses (4.0 vs 3.2 percent), and intensive reinduction (4.8 percent vs 3.3 percent), but these increases were counterbalanced by reductions in
JCI - Rearrangements of the tal-1 locus as clonal markers for T cell acute lymphoblastic leukemia.
Normal and aberrant immune receptor gene assembly each produce site-specific DNA rearrangements in leukemic lymphoblasts. In either case, these rearrangements provide useful clonal markers for the leukemias in question. In the t(1;14)(p34;q11) translocation associated with T cell acute lymphoblastic leukemia (T-ALL), the breakpoints on chromosome 1 interrupt the tal-1 gene. A site-specific deletion interrupts the same gene in an additional 26% of T-ALL. Thus, nearly one-third of these leukemias contain clustered rearrangements of the tal-1 locus. To test whether these rearrangements can serve as markers for residual disease, we monitored four patients with T-ALL; three of the leukemias contained a deleted (tald) and one a translocated (talt) tal-1 allele. These alleles were recognized by a sensitive amplification/hybridization assay. tald alleles were found in the blood of one patient during the 4th mo of treatment but not thereafter. Using a quantitative assay to measure the fraction of tald ...
Composite Index for Risk Prediction in Relapsed Childhood Acute Lymphoblastic Leukaemia - ePrints - Newcastle University
BackgroundSomatic genetic abnormalities are key initiators and drivers of disease in acute lymphoblastic leukaemia (ALL). Several chromosomal abnormalities have proven clinical utility as prognostic and predictive biomarkers at initial diagnosis. However, the role of genetic biomarkers in relapsed ALL is less well understood and has rarely been studied comprehensively within a clinical trial.AimsTo evaluate the role of genetics in predicting outcome among children with relapsed B-cell precursor ALL treated on the international trial, ALLR3.MethodsWe analysed cytogenetic, copy number alteration (CNA) and sequence mutation data at relapse in representative cohorts of patients. Patients with a very early relapse (,18 months from first diagnosis) and those patients with an isolated marrow relapse who had an early relapse (,6 months from stopping frontline therapy) were treated as clinical high risk (HR) whereas all other patients were treated as clinical standard risk (SR).ResultsClinical HR ...
Leicester Research Archive: Augmentation of the immunogenicity of acute lymphoblastic leukaemia in vitro
Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease of different immuno-phenotypically defined subtypes. Although successful conventional therapies are available, for a proportion of patients (approximately 30%) these are ultimately unsuccessful. ALL relapse is a result of the failure of the immune system to recognise these malignant cells and down regulation of crucial molecules required for cognate CD4+ T-cell recognition has been postulated as a means of immune escape. This study has concentrated on the augmentation of the immunogenicity of B-cell ALL to facilitate the generation of an anti-leukaemic immune response.;The initial gene therapy approach to enhancing ALL immunogenicity relied upon the successful transfection of primary ALL cells with a range of constructs carrying immunomodulatory genes, and the development of a protocol to routinely establish ALL cell lines from primary cultures, thus enabling the use of low-yield transfection systems to introduce recombinant DNA ...
Experiences with Acute lymphoblastic leukaemia | HealthUnlocked
Read posts from people who have experience with Acute lymphoblastic leukaemia. Find communities that can answer your questions and offer insights.
Acute Lymphocytic Leukemia | Health Information | MedCentral Health System
Acute Lymphocytic Leukemia What is acute lymphocytic leukemia? Acute lymphocytic leukemia (ALL) is a cancer of the blood in which too many lymphocytes, a type of white blood cell, are produced by the bone marrow and by organs of the lymph system. Normally, the lymphocytes fight infection. But, in ALL, the cells are immature and overabundant. They crowd out other blood cells, and may collect in the blood, bone marrow, and lymph tissue. Acute leukemia can occur over a short period of days to weeks. Chromo...
Immunogenicity and cross-reactivity of a novel mutant recombinant hCGb-protein : WestminsterResearch
Porakishvili, N., Kulikova, N., Jewell, A.P., Youinou, P.Y., Yong, K.L., Nathwani, A., Heelan, B., Duke, V., Hamblin, T.J., Wallace, P., Ely, P., Clark, E.A. and Lydyard, P.M. 2005. Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. British Journal of Haematology. 131 (3), pp. 313-319. https://doi.org/10.1111/j.1365-2141.2005.05775.x B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients ...
Analysis of ZAP70 expression in adult acute lymphoblastic leukaemia by real time quantitative PCR | Molecular Cytogenetics |...
ZAP70 gene expression is associated with poor prognosis in B-cell lymphoproliferative disorders especially chronic lymphocytic leukaemia (CLL) but its role in adult B-ALL has not been established. On diagnostic samples from 76 patients with adult ALL (65 with B-ALL and 11 with T-ALL) ZAP70 mRNA expression levels were studied by real time-quantitative PCR (RT-qPCR) analysis. A broad distribution of ZAP70 expression was observed in ALL, ranging from 0.002 to 5.3 fold that of the ZAP70 positive Jurkat reference cell line. No association was observed between expression levels and the presence of specific cytogenetic abnormalities. Five cases, including one case of T-ALL, had ZAP70 expression above the level of the Jurkat reference cell line. Our results confirm the frequent expression of ZAP70 in adult ALL. Limited comparisons made did highlight poor-risk patients with high ZAP70 expression, but due to lack of clinical information on patient samples we were unable to directly assess the impact on disease
Search Results - kamal mubarak
This invention is a novel therapy for cancer using Hox B4 to induce apoptosis in leukemia cell lines. Background & Unmet Need: B‑cell chronic lymphocytic leukemia is the most common type of leukemia in adults. The B cells grow uncontrollably and invade the bone marrow and blood where they crowd out the healthy cells. There is a need to ...
DMOZ - Health: Conditions and Diseases: Cancer: Hematologic: Leukemia: Acute Lymphocytic
A type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Common leukemia also called acute lymphoblastic leukemia and acute lymphoid leukemia (ALL). Generally occurs in children under the age of ten, but it can appear in any age group. ALL or acute means that the disease can get worse quickly. Treatment may depend on the age of the patient as ALL is referred to as either Adult acute lymphoblastic leukemia or Childhood acute lymphoblastic leukemia.
CD5 antibodies, human - Primary antibodies - Antibodies - MACS Flow Cytometry - Products - Miltenyi Biotec - USA
Clone REA782 recognizes the human CD5 antigen, a 67 kDa single-chain transmembrane glycoprotein also known as T1 or Leu-1. It is expressed on most thymocytes, the majority of peripheral T cells, a subpopulation of B cells, and B cell chronic lymphocytic leukemia (B-CLL) cells. CD5 is a receptor for the B cell antigen CD72 and plays a role in T cell activation. Additional information: Clone REA782 displays negligible binding to Fc receptors. - USA